Effects of Altering Heparan Sulfate Proteoglycan Binding and Capsid Hydrophilicity on Retinal Transduction by Adeno-associated Virus
Open accessThe DOI matches its Crossref record; 69 of the 69 references it cites were found in a registry or an index.
Abstract
Rationally guided engineering of AAV capsids aims to create new generations of vectors with enhanced potential for human gene therapy. By applying rational design principles to AAV2-based capsids, we evaluated the influence of hydrophilic and hydrophobic amino acid mutations on retinal transduction as it relates to vector administration route.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The VP3 VIII variable region of AAV2 has been shown to assist AAV2 in entering cells by recognizing the heparan sulfate proteoglycan (HSPG) site on the cell surface receptor43,55,56.”
From An adeno-associated virus variant enabling efficient ocular-directed gene delivery across species (2024) · cites this paper as [43]
Citations
Cites
Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method
Livak, K. J., & Schmittgen, T. D. (2001) · Methods · doi:10.1006/meth.2001.1262 · Cited by 180,860
Mutation of the mouse klotho gene leads to a syndrome resembling ageing
Kuro-o, M., Matsumura, Y., Aizawa, H., Kawaguchi, H., Suga, T., Utsugi, T., Ohyama, Y., Kurabayashi, M., Kaname, T., Kume, E., et al. (1997) · Nature · doi:10.1038/36285 · Cited by 3,837
Summerford, C., & Samulski, R. J. (1998) · Journal of Virology · doi:10.1128/jvi.72.2.1438-1445.1998 · Cited by 1,406
Dalkara, D., Byrne, L. C., Klimczak, R. R., Visel, M., Yin, L., Merigan, W. H., Flannery, J. G., & Schaffer, D. V. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005708 · Cited by 734
Jacobson, S. G. (2012) · Archives of Ophthalmology · doi:10.1001/archophthalmol.2011.298 · Cited by 639
Self-citationThe atomic structure of adeno-associated virus (AAV-2), a vector for human gene therapy
Xie, Q., Bu, W., Bhatia, S., Hare, J., Somasundaram, T., Azzi, A., & Chapman, M. S. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.162250899 · Cited by 612
Production and purification of serotype 1, 2, and 5 recombinant adeno-associated viral vectors
Zolotukhin, S., Potter, M., Zolotukhin, I., Sakai, Y., Loiler, S., Fraites, T. J., Chiodo, V. A., Phillipsberg, T., Muzyczka, N., Hauswirth, W. W., et al. (2002) · Methods · doi:10.1016/s1046-2023(02)00220-7 · Cited by 565
Zhong, L., Li, B., Mah, C. S., Govindasamy, L., Agbandje-McKenna, M., Cooper, M., Herzog, R. W., Zolotukhin, I., Warrington, K. H., Weigel-Van Aken, K. A., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0802866105 · Cited by 558 · cited 1×
“bic mutations (namely, Y-F and T-V) on rAAV2 have been shown in numerous studies to confer an enhancement of transduction (16, 25, 46, 47).”
BackgroundSelf-citationInfectious entry pathway of adeno-associated virus and adeno-associated virus vectors
Bartlett, J. S., Wilcher, R., & Samulski, R. J. (2000) · Journal of Virology · doi:10.1128/jvi.74.6.2777-2785.2000 · Cited by 532 · cited 1×
“may behave more closely to those of other non-heparan binding serotypes (44, 45).”
BackgroundKaludov, N., Brown, K. E., Walters, R. W., Zabner, J., & Chiorini, J. A. (2001) · Journal of Virology · doi:10.1128/jvi.75.15.6884-6893.2001 · Cited by 427
Auricchio, A. (2001) · Human Molecular Genetics · doi:10.1093/hmg/10.26.3075 · Cited by 403
High-efficiency transduction of the mouse retina by tyrosine-mutant AAV serotype vectors
Petrs-Silva, H., Dinculescu, A., Li, Q., Min, S.-H., Chiodo, V., Pang, J.-J., Zhong, L., Zolotukhin, S., Srivastava, A., Lewin, A. S., et al. (2009) · Molecular Therapy · doi:10.1038/mt.2008.269 · Cited by 398 · cited 1×
“bic mutations (namely, Y-F and T-V) on rAAV2 have been shown in numerous studies to confer an enhancement of transduction (16, 25, 46, 47).”
BackgroundIdentification of a heparin-binding motif on adeno-associated virus type 2 capsids
Kern, A., Schmidt, K., Leder, C., Müller, O. J., Wobus, C. E., Bettinger, K., Von der Lieth, C. W., King, J. A., & Kleinschmidt, J. A. (2003) · Journal of Virology · doi:10.1128/jvi.77.20.11072-11081.2003 · Cited by 380
Cehajic-Kapetanovic, J., Xue, K., Martinez-Fernandez de la Camara, C., Nanda, A., Davies, A., Wood, L. J., Salvetti, A. P., Fischer, M. D., Aylward, J. W., Barnard, A. R., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0763-1 · Cited by 368
Opie, S. R., Warrington, Agbandje-McKenna, M., Zolotukhin, S., & Muzyczka, N. (2003) · Journal of Virology · doi:10.1128/jvi.77.12.6995-7006.2003 · Cited by 364
Self-citationInner limiting membrane barriers to aav-mediated retinal transduction from the vitreous
Dalkara, D., Kolstad, K. D., Caporale, N., Visel, M., Klimczak, R. R., Schaffer, D. V., & Flannery, J. G. (2009) · Molecular Therapy · doi:10.1038/mt.2009.181 · Cited by 357
Comprehensive AAV capsid fitness landscape reveals a viral gene and enables machine-guided design
Ogden, P. J., Kelsic, E. D., Sinai, S., & Church, G. M. (2019) · Science · doi:10.1126/science.aaw2900 · Cited by 356 · cited 1×
“who report that positively charged amino acid substitutions more often result in decreased capsid fitness for AAV2 (31).”
BackgroundWu, Z., Miller, E., Agbandje-McKenna, M., & Samulski, R. J. (2006) · Journal of Virology · doi:10.1128/jvi.00895-06 · Cited by 328
Self-citationZabner, J., Seiler, M., Walters, R., Kotin, R. M., Fulgeras, W., Davidson, B. L., & Chiorini, J. A. (2000) · Journal of Virology · doi:10.1128/jvi.74.8.3852-3858.2000 · Cited by 315
Halbert, C. L., Allen, J. M., & Miller, A. D. (2001) · Journal of Virology · doi:10.1128/jvi.75.14.6615-6624.2001 · Cited by 314
Akimoto, M., Cheng, H., Zhu, D., Brzezinski, J. A., Khanna, R., Filippova, E., Oh, E. C. T., Jing, Y., Linares, J.-L., Brooks, M., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0508214103 · Cited by 314
Novel properties of tyrosine-mutant AAV2 vectors in the mouse retina
Petrs-Silva, H., Dinculescu, A., Li, Q., Deng, W.-T., Pang, J.-J., Min, S.-H., Chiodo, V., Neeley, A. W., Govindasamy, L., Bennett, A., et al. (2011) · Molecular Therapy · doi:10.1038/mt.2010.234 · Cited by 267
Self-citationWu, Z., Asokan, A., Grieger, J. C., Govindasamy, L., Agbandje-McKenna, M., & Samulski, R. J. (2006) · Journal of Virology · doi:10.1128/jvi.01288-06 · Cited by 237
Self-citationZhong, L., Li, B., Jayandharan, G., Mah, C. S., Govindasamy, L., Agbandje-McKenna, M., Herzog, R. W., Weigel-Van Aken, K. A., Hobbs, J. A., Zolotukhin, S., et al. (2008) · Virology · doi:10.1016/j.virol.2008.08.027 · Cited by 232
Self-citationRole for highly regulated rep gene expression in adeno-associated virus vector production
Li, J., Samulski, R. J., & Xiao, X. (1997) · Journal of Virology · doi:10.1128/jvi.71.7.5236-5243.1997 · Cited by 227
Yan, Z., Zak, R., Luxton, G. W. G., Ritchie, T. C., Bantel-Schaal, U., & Engelhardt, J. F. (2002) · Journal of Virology · doi:10.1128/jvi.76.5.2043-2053.2002 · Cited by 222
Klimczak, R. R., Koerber, J. T., Dalkara, D., Flannery, J. G., & Schaffer, D. V. (2009) · PLoS ONE · doi:10.1371/journal.pone.0007467 · Cited by 210
Asokan, A., Hamra, J. B., Govindasamy, L., Agbandje-McKenna, M., & Samulski, R. J. (2006) · Journal of Virology · doi:10.1128/jvi.00843-06 · Cited by 183
Self-citationTargeting photoreceptors via intravitreal delivery using novel, capsid-mutated AAV vectors
Kay, C. N., Ryals, R. C., Aslanidi, G. V., Min, S. H., Ruan, Q., Sun, J., Dyka, F. M., Kasuga, D., Ayala, A. E., Van Vliet, K., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0062097 · Cited by 168 · cited 3×
“Injections were performed under a Leica M80 stereomicroscope as previously reported (27, 65).”
BackgroundMethodSelf-citationChoroideremia gene therapy phase 2 clinical trial: 24-month results
Lam, B. L., Davis, J. L., Gregori, N. Z., MacLaren, R. E., Girach, A., Verriotto, J. D., Rodriguez, B., Rosa, P. R., Zhang, X., & Feuer, W. J. (2019) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2018.09.012 · Cited by 161 · cited 1×
“than rAAV2(Y444F)DHS in nonrod retinal cells [F(3,18) = 13.”
BackgroundConstable, I. J., Pierce, C. M., Lai, C.-M., Magno, A. L., Degli-Esposti, M. A., French, M. A., McAllister, I. L., Butler, S., Barone, S. B., Schwartz, S. D., et al. (2016) · EBioMedicine · doi:10.1016/j.ebiom.2016.11.016 · Cited by 152
Structural Characterization of the Dual Glycan Binding Adeno-Associated Virus Serotype 6
Ng, R., Govindasamy, L., Gurda, B. L., McKenna, R., Kozyreva, O. G., Samulski, R. J., Parent, K. N., Baker, T. S., & Agbandje-McKenna, M. (2010) · Journal of Virology · doi:10.1128/jvi.01235-10 · Cited by 143
Self-citationKhani, S. C., Pawlyk, B. S., Bulgakov, O. V., Kasperek, E., Young, J. E., Adamian, M., Sun, X., Smith, A. J., Ali, R. R., & Li, T. (2007) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.07-0257 · Cited by 139
Bantel-Schaal, U., Hub, B., & Kartenbeck, J. (2002) · Journal of Virology · doi:10.1128/jvi.76.5.2340-2349.2002 · Cited by 129
Mietzsch, M., Broecker, F., Reinhardt, A., Seeberger, P. H., & Heilbronn, R. (2014) · Journal of Virology · doi:10.1128/jvi.03371-13 · Cited by 129
Adeno-associated virus-2 and its primary cellular receptor—Cryo-EM structure of a heparin complex
O'Donnell, J., Taylor, K. A., & Chapman, M. S. (2009) · Virology · doi:10.1016/j.virol.2008.11.037 · Cited by 125
Noninvasive gene delivery to foveal cones for vision restoration
Khabou, H., Garita-Hernandez, M., Chaffiol, A., Reichman, S., Jaillard, C., Brazhnikova, E., Bertin, S., Forster, V., Desrosiers, M., Winckler, C., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.96029 · Cited by 124 · cited 2×
“ally spread through the retina, similar to AAV9 (55) and the recently discovered AAV44.”
BackgroundBoye, S. E., Alexander, J. J., Boye, S. L., Witherspoon, C. D., Sandefer, K. J., Conlon, T. J., Erger, K., Sun, J., Ryals, R., Chiodo, V. A., et al. (2012) · Human Gene Therapy · doi:10.1089/hum.2012.125 · Cited by 117
Self-citationFinn, J. D., Hui, D., Downey, H. D., Dunn, D., Pien, G. C., Mingozzi, F., Zhou, S., & High, K. A. (2010) · Molecular Therapy · doi:10.1038/mt.2009.257 · Cited by 115
Tordo, J., O’Leary, C., Antunes, A. S. L. M., Palomar, N., Aldrin-Kirk, P., Basche, M., Bennett, A., D’Souza, Z., Gleitz, H., Godwin, A., et al. (2018) · Brain · doi:10.1093/brain/awy126 · Cited by 113 · cited 1×
“ies have investigated infectious rAAV2-based variants that are deficient in HSPG binding (12, 13, 42, 43).”
BackgroundSelf-citationSubretinal injections in rodent eyes: effects on electrophysiology and histology of rat retina.
Timmers, A. M., Zhang, H., Squitieri, A., & Gonzalez-Pola, C. (2001) · PubMed · Cited by 110
Self-citationNam, H.-J., Gurda, B. L., McKenna, R., Potter, M., Byrne, B., Salganik, M., Muzyczka, N., & Agbandje-McKenna, M. (2011) · Journal of Virology · doi:10.1128/jvi.05305-11 · Cited by 108 · cited 1×
“R389 and Y704 are important for pH-mediated endolysosomal trafficking (28, 29), and N511 binds the integrin coreceptor avb1 (30).”
BackgroundSelf-citationLotery, A. J., Yang, G. S., Mullins, R. F., Russell, S. R., Schmidt, M., Stone, E. M., Lindbloom, J. D., Chiorini, J. A., Kotin, R. M., & Davidson, B. L. (2003) · Human Gene Therapy · doi:10.1089/104303403322542301 · Cited by 107 · cited 1×
“having a functional phenotype in rAAV2 retinal transduction via SRI (13, 14, 21, 22),”
BackgroundAAV9 Vector: a Novel modality in gene therapy for spinal muscular atrophy
Pattali, R. K., Mou, Y., & Li, X.-J. (2019) · Gene Therapy · doi:10.1038/s41434-019-0085-4 · Cited by 107
Aslanidi, G. V., Rivers, A. E., Ortiz, L., Song, L., Ling, C., Govindasamy, L., Van Vliet, K., Tan, M., Agbandje-McKenna, M., & Srivastava, A. (2013) · PLoS ONE · doi:10.1371/journal.pone.0059142 · Cited by 95
Self-citationEvidence for pH-Dependent Protease Activity in the Adeno-Associated Virus Capsid
Salganik, M., Venkatakrishnan, B., Bennett, A., Lins, B., Yarbrough, J., Muzyczka, N., Agbandje-McKenna, M., & McKenna, R. (2012) · Journal of Virology · doi:10.1128/jvi.01717-12 · Cited by 80
Self-citationBoye, S. L., Bennett, A., Scalabrino, M. L., McCullough, K. T., Van Vliet, K., Choudhury, S., Ruan, Q., Peterson, J., Agbandje-McKenna, M., & Boye, S. E. (2016) · Journal of Virology · doi:10.1128/jvi.00200-16 · Cited by 79
Self-citationCrosson, S. M., Dib, P., Smith, J. K., & Zolotukhin, S. (2018) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2018.05.001 · Cited by 79
Self-citationRationally Engineered AAV Capsids Improve Transduction and Volumetric Spread in the CNS
Kanaan, N. M., Sellnow, R. C., Boye, S. L., Coberly, B., Bennett, A., Agbandje-McKenna, M., Sortwell, C. E., Hauswirth, W. W., Boye, S. E., & Manfredsson, F. P. (2017) · Molecular Therapy - Nucleic Acids · doi:10.1016/j.omtn.2017.06.011 · Cited by 72
Self-citationFe(III) improves antioxidant and cytoprotecting activities of mangiferin
Andreu, G. L. P., Sánchez-Baldoquín, C., Ávila-González, R., Delgado, R., Naal, Z., & Curti, C. (2006) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2006.07.040 · Cited by 67
Li, M., Jayandharan, G. R., Li, B., Ling, C., Ma, W., Srivastava, A., & Zhong, L. (2010) · Human Gene Therapy · doi:10.1089/hum.2010.005 · Cited by 67
Haire, S. E., Pang, J., Boye, S. L., Sokal, I., Craft, C. M., Palczewski, K., Hauswirth, W. W., & Semple-Rowland, S. L. (2006) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.06-0086 · Cited by 66
Self-citationIida, A., Takino, N., Miyauchi, H., Shimazaki, K., & Muramatsu, S.-I. (2013) · BioMed Research International · doi:10.1155/2013/974819 · Cited by 62
Woodard, K. T., Liang, K. J., Bennett, W. C., & Samulski, R. J. (2016) · Journal of Virology · doi:10.1128/jvi.01568-16 · Cited by 59 · cited 3×
“is required for retinal transduction via IVI (12, 13).”
BackgroundRestoring the natural tropism of AAV2 vectors for human liver
Cabanes-Creus, M., Hallwirth, C. V., Westhaus, A., Ng, B. H., Liao, S. H. Y., Zhu, E., Navarro, R. G., Baltazar, G., Drouyer, M., Scott, S., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aba3312 · Cited by 58
Self-citationAttachment of adeno-associated virus type 3H to fibroblast growth factor receptor 1
Blackburn, S. D., Steadman, R., & Johnson, F. B. (2005) · Archives of Virology · doi:10.1007/s00705-005-0650-6 · Cited by 57
Identification of the heparin binding site on adeno-associated virus serotype 3B (AAV-3B)
Lerch, T. F., & Chapman, M. S. (2012) · Virology · doi:10.1016/j.virol.2011.10.007 · Cited by 54
Reid, C. A., Ertel, K. J., & Lipinski, D. M. (2017) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.17-22281 · Cited by 51
Evaluation of AAV-DJ vector for retinal gene therapy
Katada, Y., Kobayashi, K., Tsubota, K., & Kurihara, T. (2019) · PeerJ · doi:10.7717/peerj.6317 · Cited by 46
Cabanes‐Creus, M., Westhaus, A., Navarro, R. G., Baltazar, G., Zhu, E., Amaya, A. K., Liao, S. H. Y., Scott, S., Sallard, E., Dilworth, K. L., et al. (2020) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2020.05.004 · Cited by 45
Self-citationVoretigene Neparvovec: A Review in RPE65 Mutation-Associated Inherited Retinal Dystrophy
Kang, C., & Scott, L. J. (2020) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-020-00475-6 · Cited by 43
(2011) · PubMed Central · Cited by 41
Self-citationRationally designed AAV2 and AAVrh8R capsids provide improved transduction in the retina and brain
Sullivan, J. A., Stanek, L. M., Lukason, M. J., Bu, J., Osmond, S. R., Barry, E. A., O’Riordan, C. R., Shihabuddin, L. S., Cheng, S. H., & Scaria, A. (2018) · Gene Therapy · doi:10.1038/s41434-018-0017-8 · Cited by 37 · cited 1×
“8R vectors once HSPG binding was grafted onto the vectors by targeted mutagenesis (14, 56).”
MethodArnett, A. L. H., Beutler, L. R., Quintana, A., Allen, J., Finn, E., Palmiter, R. D., & Chamberlain, J. S. (2013) · Gene Therapy · doi:10.1038/gt.2012.60 · Cited by 34
Novel AAV44.9-Based Vectors Display Exceptional Characteristics for Retinal Gene Therapy
Boye, S. L., Choudhury, S., Crosson, S., Di Pasquale, G., Afione, S., Mellen, R., Makal, V., Calabro, K. R., Fajardo, D., Peterson, J., et al. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.04.002 · Cited by 29 · cited 6×
“8R vectors once HSPG binding was grafted onto the vectors by targeted mutagenesis (14, 56).”
BackgroundMethodInfluentialSelf-citationVirus Binding and Internalization Assay for Adeno-associated Virus
Berry, G. E., & Tse, L. V. (2017) · BIO-PROTOCOL · doi:10.21769/bioprotoc.2110 · Cited by 28
Lee, S. H., Sim, K. S., Kim, C. Y., & Park, T. K. (2019) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2019.06.009 · Cited by 27
Gorbatyuk, O. S., Warrington, K. H., Gorbatyuk, M. S., Zolotukhin, I., Lewin, A. S., & Muzyczka, N. (2019) · Virus Research · doi:10.1016/j.virusres.2019.197771 · Cited by 18
Retinal Gene Therapy Using Adeno-Associated Viral Vectors: Multiple Applications for a Small Virus
Hauswirth, W. W. (2014) · Human Gene Therapy · doi:10.1089/hum.2014.2530 · Cited by 12
Cited by
An adeno-associated virus variant enabling efficient ocular-directed gene delivery across species
Luo, S., Jiang, H., Li, Q., Qin, Y., Yang, S., Li, J., Xu, L., Gou, Y., Zhang, Y., Liu, F., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-48221-4 · Cited by 39
Machine-learning-guided Directed Evolution for AAV Capsid Engineering
Fu, X., Suo, H., Zhang, J., & Chen, D. (2024) · Current Pharmaceutical Design · doi:10.2174/0113816128286593240226060318 · Cited by 25
Adeno-Associated Virus-Mediated Gene Therapy
Zaman, H., Khan, A. U., Khan, K., Toheed, S., Abdullah, M., Zeeshan, H. M., Hameed, A., Umar, M., Shahid, M., Malik, K. A., et al. (2023) · Critical Reviews in Eukaryotic Gene Expression · doi:10.1615/critreveukaryotgeneexpr.2023048135 · Cited by 12
Clerck, K. D., Smedt, S. C. D., Remaut, K., & Peynshaert, K. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.113849 · Cited by 11
Engineered AAV capsid transport mutants overcome transduction deficiencies in the aged CNS
Sandoval, I. M., Kelley, C. M., Bernal-Conde, L. D., Steece‐Collier, K., Marmion, D. J., Davidsson, M., Crosson, S. M., Boye, S. L., Boye, S. L., & Manfredsson, F. P. (2024) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2024.102332 · Cited by 9
Self-citation
Metadata
- Authors
- Crosson, S. M., Bennett, A., Fajardo, D., Peterson, J. J., Zhang, H., Li, W., Leahy, M. T., Jennings, C. K., Boyd, R. F., Boye, S. L., Agbandje-McKenna, M., & Boye, S. E.
- Affiliations
- University of Florida Health (US)
- University of Florida (US)
- Charles River Laboratories (United States) (US)
- Department of Biochemistry and Molecular Biology, University of Florida, Gainesville, Florida, USA
- Corresponding author
- Boye, Shannon E.
- Venue
- Journal of Virology
- Publisher
- American Society for Microbiology
- Published
- 2021-04-26
- Volume
- 95
- Issue
- 10
- ISSN
- 0022-538X (ISSN-L)
- 1098-5514
- PMC
- PMC8139652
- OpenAlex
- W3133743237
- Cited by
- 16
- References
- 69
- Citations by year
- 2026: 4 · 2025: 6 · 2024: 4 · 2023: 2
- FWCI
- 0.85
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Licence
- doi.org/10.1128/ASMCopyrightv2 (vor)
- journals.asm.org/non-commercial-tdm-license (tdm)
- Locations
- Journal of Virology (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Foundation Fighting Blindness
- AchromaCorp
- HHS | NIH | National Eye Institute (R01EY025752, R01EY024280)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- adeno-associated virus, amino acid mutations, retinal transduction, photoreceptors, subretinal injection, lateral spreading, gene therapy vectors, retinal disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.